Patent for Copaxone ceased in 2014 , but pesumbaly the two companies are working together as NSB would need to source Copaxone part of the product or the news story attached (dated 2018) might also explain https://www.fiercepharma.com/pharma/facing-generics-from-mylan-and-novartis-teva-loses-patent-appeal-copaxone "Teva's patent failure gives long-acting Copaxone generics free rein"
Ann: NSB files new patent, page-13
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.35M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 40000 | 3.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.2¢ | 114887 | 2 |
View Market Depth
| Last trade - 11.12am 19/06/2024 (20 minute delay) ? |
| NSB (ASX) Chart |
Day chart unavailable